Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Separation or purification
Reexamination Certificate
2008-01-29
2008-01-29
Mondesi, Robert B. (Department: 1652)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Separation or purification
Reexamination Certificate
active
07323553
ABSTRACT:
The present invention relates to a method for protein purification that involves the combination of non-affinity chromatography with HPTFF.
REFERENCES:
patent: 4515893 (1985-05-01), Kung et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5091313 (1992-02-01), Chang et al.
patent: 5256294 (1993-10-01), van Reis
patent: 5256694 (1993-10-01), Wuest et al.
patent: 5490937 (1996-02-01), van Reis
patent: 5534615 (1996-07-01), Baker et al.
patent: 5622700 (1997-04-01), Jardieu et al.
patent: 5672347 (1997-09-01), Aggarwal et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5714338 (1998-02-01), Fei et al.
patent: 5721108 (1998-02-01), Robinson et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 6054051 (2000-04-01), van Reis
patent: WO 93/04173 (1993-03-01), None
patent: WO 95/19181 (1995-07-01), None
patent: WO 95/23865 (1995-09-01), None
patent: WO 96/30046 (1996-10-01), None
patent: WO 96/40210 (1996-12-01), None
patent: WO 97/26912 (1997-07-01), None
patent: WO 98/06248 (1998-02-01), None
patent: WO 98/23761 (1998-06-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 98/51793 (1998-11-01), None
patent: WO 00/75348 (2000-12-01), None
patent: WO 01/40309 (2001-06-01), None
Kathy Liszewski, Stragedies for Mab purification include cation exchange and tangential flow, Aug. 1997, Genetic Engineering News, pp. 16 and 35.
Aruffo et al., “CD44 Is the Principle Cell Surface Receptor for Hyaluronate”, Cell, 61, 1990, pp. 1303-1313.
Berg et al., “Bispecific Antibodies that Mediate Killing of Cells Infected with Human Immunodeficiency Virus of Any Strain”, Proc. Natl. Acad. Sci. USA, 88, Jun. 1991, pp. 4723-4727.
Boschetti, E. et al, “Genetic Engineering News”, 20 (13), 2000, pp. 34 & 51.
Brennan et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1Fragments”, Science, 229, Jul. 1985, pp. 81-83.
Brodeur et al., “Mouse-Human Myeloma Partners for the Production of Heterohybridomas”, Monoclonal Antibody Production Techniques and Applications, New York: Marcel Dekker, Inc., 1987, pp. 51-63.
Carter et al., “High LevelEscherichia coliExpression and Production of a Bivalent Humanized Antibody Fragment”, Bio/Technology, 10, Feb. 1992, pp. 163-167.
Carter et al., “Humanization of an Anti-p185HER2Antibody For Human Cancer Therapy”, Proc. Natl. Acad. Sci. USA, 89, May 1992, pp. 4285-4289.
Ceriani et al., “Biological Activity of Two Humanized Antibodies against Two Different Breast Cancer Antigens and Comparison to Their Original Murine Forms”, Cancer Research (Suppl), 55, Dec. 1995, pp. 5852s-5856s.
Chamow et al., “A Humanized, Bispecific Immunoadhesin-Antibody That Retargets CD3+Effectors to Kill HIV-1-Infected Cells”, Journal of Immunology, 153, 1994, pp. 4268-4280.
Chothia et al, “Canonical Structures for the Hypervariable Regions of Immunoglobulins”, J. Mol. Biol., 196, 1987, pp. 901-917.
Choy et al., “Percentage of Anti-CD4 Monoclonal Antibody-Coated Lymphocytes In The Rheumatoid Joint Is Associated With Clinical Improvement”, Arthritis Rheumatism, 39, Jan. 1996, pp. 52-56.
Clackson et al., “Making Antibody Fragments Using Phage Display Libraries”, Nature, 352, Aug. 1991, pp. 624-628.
Desroches et al, “Regulation and Functional Involvement of Distinct Determinants of Leucocyte Function-Associated Antigen 1 (LFA-1) in T-Cell Activation In Vitro”, Scand. J. Immunol., 33, 1991, pp. 277-286.
Dhainaut et al., “CDP571, A Humanized Antibody to Human Tumor Necrosis Factor-α: Safety, Pharmacokinetics, Immune Response, and Influence of the Antibody on Cytokine Concentrations in Patients with Septic Shock”, Critical Care Medicine, 23 (9), 1995, pp. 1461-1469.
Duchosal et al., “Immunization of hu-PBL-SCID Mice and the Rescue of Human Monoclonal Fab Fragments Through Combinatorial Libraries”, Nature, 355, Jan. 1992, pp. 258-262.
Ellis et al., “Engineered Anti-CD38 Monoclonal Antibodies for Immunotherapy of Multiple Myeloma”, The Journal of Immunology, 155, 1995, pp. 925-937.
Goding, “Production of Monoclonal Antibodies”, Monoclonal Antibodies: Principles and Practice, Academic Press, 1986, pp. 59-103.
Graziano et al., “Construction and Characterization of a Humanized Anti -γ-lg Receptor Type I (FcγRI) Monoclonal Antibody”, The Journal of Immunology, 155, 1995, pp. 4996-5002.
Gruber et al., “Efficient Tumor Cell Lysis Mediated by a BiSpecificSingle Chain Antibody Expressed inEscherichia coli”, Journal of Immunology, 152, 1994, pp. 5368-5374.
Gueffroy Ph.d., Donald E., “Buffers: A Guide for the Preparation and Use of Buffers in Biological Systems”, Calbiochem Corporation, 1975, pp. 3-21.
Hildreth et al., “A Human Lymphocyte-Associated Antigen Involved in Cell-Mediated Lympholysis”, European Journal of Immunology, 13, 1983, pp. 202-208.
Hoogenboom et al., “By-Passing Immunisation: Human Antibodies from Synthetic Repertoires of Germline VHGene Segments Rearranged in Vitro”, J. Mol. Biol., 227, 1992, pp. 381-388.
Hoogenboom et al., “Construction and Expression of Antibody-Tumor Necrosis Factor Fusion Proteins”, Molecular Immunology, 28 (9), 1991, pp. 1027-1037.
Hourmant et al., “Administration of an Anti-CD11a Monoclonal Antibody in Recipients of Kidney Transplantation”, Transplantation, 58 (3), Aug. 1994, pp. 377-380.
Jacobovits et al., “Germ-Line Transmission and Expression of a Human-Derived Yeast Artificial Chromosome”, Nature, 362, Mar. 1993, pp. 255-258.
Jacobovits et al., “Analysis of Homozygous Mutant Chimeric Mice: Deletion of the Immunoglobin Heavy-Chain Joining Region Blocks B-Cell Development and Antibody Production”, Proc. Natl. Acad. Sci. USA, 90, Mar. 1993, pp. 2551-2555.
Jones et al., “Replacing the Complementarity-Determining Regions in a Human Antibody with Those From a Mouse”, Nature, 321, May 1986, pp. 522-525.
Jurcic et al., “Radiolabeled Anti-CD33 Monoclonal Antibody M195 for Myeloid Leukemias”, Cancer Research (Suppl.), 55, Dec. 1995, pp. 5908s-5910s.
Juweid et al., “Treatment of Non-Hodgkin's Lymphoma with Radiolabeled Murine, Chimeric, or Humanized LL2, and Anti-CD22 Monoclonal Antibody”, Cancer Research (Suppl.), 55, :Dec. 1995, pp. 5899s-5907s.
Kabat et al., “Sequences of Proteins of Immunological Interest”, U.S. Dept. of Health and Human Services, National Institute of Health, 5th edition, 1, 1991, pp. 103-108 and 324-331.
Kim et al., “The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies”, Growth Factors, 7, 1992, pp. 53-64.
Kohler et al., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity”, Nature, 256, Aug. 1975, pp. 495-497.
Kostelny et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers”, Journal of Immunology, 148, (5), Mar. 1992, pp. 1547-1553.
Kozbor et al., “A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies”, The Journal of Immunology, 133, (6), Dec. 1984, pp. 3001-3005.
Lindmark et al., “Binding of Immunoglobulins to Protein A and Immunoglobulin Levels in Mammalian Sera”, Journal of Immunological Methods, 62, 1983, pp. 1-13.
Litton et al., “Antibody-Targeted Superantigen Therapy Induces Tumor-Infiltrating Lymphocytes, Excessive Cytokine Production, and Apoptosis in Human Colon Carcinoma”, European Journal of Immunology, 26, 1996, pp. 1-9.
Lorenz et al., “In Vivo Blockade of TNF-α by Intravenous Infusion of a Chimeric Monoclonal TNF-α Antibody in Patients with Rheumatoid Arthritis”, The Journal of Immunology, 156, 1996,
Fahrner Robert
Follman Deborah
Lebreton Benedicte
van Reis Robert
Conley Deirdre L.
Dreger, Esq. Ginger R.
Genentech Inc.
Heller Ehrman LLP
Mondesi Robert B.
LandOfFree
Non-affinity purification of proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-affinity purification of proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-affinity purification of proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2806265